{
    "nct_id": "NCT03810807",
    "official_title": "Phase 1 Study of Combination Dacomitinib and Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers",
    "inclusion_criteria": "* Written informed consent\n* Advanced biopsy-proven metastatic non-small cell lung cancer\n* Somatic activating mutation in EGFR in a tumor biopsy\n* No prior EGFR inhibitor treatment (gefitinib, afatinib, erlotinib, dacomitinib, osimertinib) however, prior treatment with other chemotherapies are allowed\n* Archival tissue available from a pre-treatment tumor biopsy or willing to undergo a tumor biopsy prior to study initiation.\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\n* Karnofsky performance status (KPS) ≥ 70%\n* Age >18 years old\n* Ability to swallow oral medication\n* Agree to use effective methods of contraception from the time of screening until 3 months after treatment discontinuation (for males and females of child-bearing potential)\n* Adequate organ function\n\n  * AST, ALT ≤ 3 x ULN\n  * Total bilirubin ≤1.5x ULN\n  * Creatinine ≤ 1.5x ULN OR calculated creatinine clearance ≥ 60ml/min\n  * Absolute neutrophil count (ANC) ≥ 1000 cells/mm^3\n  * Hemoglobin≥9.0 g/dL\n  * Platelets ≥100,000/mm^3\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Pregnant or lactating women\n* Any radiotherapy within 1 week of starting treatment on protocol.\n* Any major surgery within 1 weeks of starting treatment on protocol.\n* Any evidence of active clinically significant interstitial lung disease\n* A mean QTc >470ms (Fridericia\"s correction), clinically important arrhythmia, conduction or morphology of resting ECG (eg complete LBBB, 1st -3rd degree heart block, any factors that increase the risk of QTc prolongation or risk of arrhythmia)\n* Cardiovascular disease or cerebrovascular disease, CVA or MI < 6 months prior to study enrollment, unstable angina, NYHA >Grade II CHF, or serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment\n* History of pneumonitis or interstitial lung disease (ILD), drug induced ILD, radiation pneumonitits that required steroid treatment, and any evidence of clinically active ILD\n* Serious chronic GI conditions associated with diarrhea\n* Symptomatic, unstable brain metastases requiring escalating doses of steroids\n* Continue to have unresolved > CTCAE grade 1 toxicity from any previous treatment",
    "miscellaneous_criteria": ""
}